Pancreatic ductal adenocarcinoma (PDAC) is often associated with overexpression of TGFb. Given its tumor suppressor functions, it is unclear whether TGF-b is a valid therapeutic target for PDAC. Here, we found that proliferating pancreatic cancer cells (PCCs) from human PDAC patients and multiple murine models of PDAC (mPDAC) often exhibit abundant levels of phosphorylated retinoblastoma 1 (RB) and Smad2. TGF-b1 treatment enhanced proliferation of PCCs isolated from Kras G12D -driven mPDAC that lacked RB (KRC cells). This mitogenic effect was abrogated by pharmacological inhibition of type I TGF-b receptor kinase, combined inhibition of MEK/Src or MEK/PI3K, and restoration of RB expression. TGF-b1 promoted epithelial-to-mesenchymal transition (EMT), invasion, Smad2/3 phosphorylation, Src activation, Wnt reporter activity, and Smad-dependent upregulation of Wnt7b in KRC cells. Importantly, TGF-b1-induced mitogenesis was markedly attenuated by inhibition of Wnt secretion. In an in vivo syngeneic orthotopic model, inhibition of TGF-b signaling suppressed KRC cell proliferation, tumor growth, stroma formation, EMT, metastasis, ascites formation, and Wnt7b expression, and markedly prolonged survival. Together, these data indicate that RB dysfunction converts TGF-b to a mitogen that activates known oncogenic signaling pathways and upregulates Wnt7b, which synergize to promote PCC invasion, survival, and […]
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in the United States, with a dismal overall 5-year survival rate of 6% (1) . PDAC most often presents at an advanced stage with metastatic and/or extensive locally invasive disease and is associated with chemoresistance and desmoplasia (2) (3) (4) . PDACs harbor major driver mutations in the KRAS oncogene (95%) and SMAD4 (55%), TP53 (70%), and CDKN2A (90%) tumor suppressor genes, the latter also being susceptible to epigenetic silencing (3, 5) . In addition, there is overexpression of tyrosine kinase receptors and ligands (6) , constitutive activation of prosurvival pathways, including AKT and NF-κB (7, 8) , reactivation of developmental pathways, such as WNT and Notch (8, 9) , and overexpression of transforming growth factor β (TGF-β) isoforms (10) . TGF-β overexpression is associated with early recurrence following resection and decreased survival (10) , and suppression of TGF-β actions in immune-deficient orthotopic mouse models of PDAC attenuates tumor growth and metastasis (11, 12) . However, TGF-β also acts as a tumor suppressor, and in a genetically engineered mouse model (GEM) of PDAC in which oncogenic Kras is combined with p53 haploinsufficiency, disrupting TGF-β signaling enhanced PDAC progression (13) . Therefore, the benefit of targeting TGF-β in PDAC is not clearly defined.
Oncogenic KRAS is the initiating molecular alteration in PDAC in humans (hPDAC) and mice (mPDAC) (14) (15) (16) (17) (18) (19) . KC (which stands for Kras;Pdx1-Cre recombinase) mice carry an oncogenic Kras (Kras G12D ) allele that is silenced by an upstream LoxP-Stop-LoxP (LSL) element, but activated following Cre-mediated recombination (14) . KC mice develop low-grade pancreatic intraepithelial neoplasia (PanIN) and acinar-to-ductal metaplasia (ADM) by 2 months of age (14) . By 10 months, KC mice develop mPDAC at moderate penetrance (14) . PanIN are an important feature of PDAC initiation in both humans and GEMs, and PanIN progression to mPDAC is accelerated by deletion of the p53 (16) , p16 Ink4a /p19 Arf (Cdkn2a) (17) , Smad4 (15) , p16 Ink4a (19) , and RB (18) tumor suppressors. However, the RB1 gene is rarely mutated in hPDAC (20) , and given the high frequency of KRAS and CDKN2A mutations occurring in conjunction with the overexpression of multiple tyrosine kinase receptors and increased cyclin D1 levels (6) , the loss of RB function in PDAC presumably does not drive its pathobiology.
We report here that both RB and Smad2 were frequently phosphorylated in Ki67-positive pancreatic cancer cells (PCCs) in hPDAC, indicating that RB was functionally inactivated in proliferating PCCs in the face of robust TGF-β signaling. We also show that in murine PanIN arising in a GEM in which the pancreas only harbors oncogenic Kras (KC mice), there was a paucity of phosphorylated RB (p-RB) and Ki67, but abundant phosphorylated Smad2 (p-Smad2) and p21 Waf1 , a TGF-β-induced gene that inhibits proliferation (21) . By contrast, in mice in which oncogenic Kras was combined with either p53 (KPC mice) or p16 Ink4a (KIC mice) loss, we found that many PanIN and PCCs concomitantly exhibited p-RB, Ki67, and p-Smad2, whereas p21 Waf1 was not detectable. Moreover, in mice with oncogenic Kras and Rb1 deletion (KRC mice), p-Smad2 was abundant in proliferating PanIN and PCCs, and in all cases of mice with increased p-Smad2 in PanIN and PCCs, stromal p-Smad2 was also abundant.
Using KRC-derived PCCs, which are devoid of RB, we demonstrated that TGF-β1 enhanced proliferation while increasing Smad2/3 phosphorylation and nuclear translocation, as well as activation of Src, PI3K, and ERK. We also show that TGF-β1-induced proliferation was suppressible by RB reexpression or Wnt7b inhibition. Moreover, in a syngeneic orthotopic model of PDAC, we found that SB505124 markedly attenuated PCC proliferation, tumor growth, and metastasis, as well as ascites and stroma formation. Thus, RB dysfunction is common in PDAC, and loss of RB function converts TGF-β from a tumor suppressor to a mitogen that enhances PCC proliferation.
Results
Both RB and Smad2 are phosphorylated in proliferating pancreatic cancer cells. The ability of RB to inhibit cell cycle progression requires its activation through hypophosphorylation (22) , and TGF-β-mediated growth inhibition of human PCCs depends on maintaining RB in a hypophosphorylated state (23) . To determine whether RB is inactive in PDAC, we evaluated hPDAC tissue samples for the presence of hyperphosphorylated, inactive RB ( Figure 1A ). We found that p-RB was present in 44 of 58 PDAC samples in at least 10% of PCCs per high-power field ( Figure 1B ), suggesting that in 76% of these cancers RB was inactive. Moreover, in 8 of 8 tested PDACs, we found p-RB to be abundant in cancer cell nuclei in 72% of Ki67-positive cells ( Figure 1B and Supplemental Figure 1A ; supplemental material available online with this article; doi:10.1172/ JCI71526DS1), pointing to RB inactivation in proliferating PCCs. Phosphorylated Smad2 (p-Smad2) was also abundant in PCCs and stromal cell nuclei in all 8 tested PDACs and colocalized with 84% of Ki67-positive PCCs ( Figure 1C and Supplemental Figure 1B ). Analysis of thin (3 μm) serial sections revealed that nuclear p-RB and p-Smad2 were abundant in the PCCs, frequently colocalizing with Ki67 (Supplemental Figure 1C ). By contrast, we rarely observed p21 Waf1 immunoreactivity ( Figure 1D ).
We next examined p-Smad2, p-RB, p21 Waf1 , and Ki67 expression in murine pancreata to evaluate their status in relation to proliferation in mPDAC precursor lesions. In KC pancreata, p-Smad2 was present in PanIN and stromal nuclei, whereas p-RB was absent, Ki67 was rarely detected, and p21 Waf1 was abundant (Supplemental Figure 2 ). Thus, active RB and upregulated p21 Waf1 combined to constrain proliferation in KC PanIN. By contrast, PanIN in KIC and KPC pancreata exhibited Ki67-positive nuclei that frequently expressed p-RB, but not p21 Waf1 , despite abundant p-Smad2 positivity in PanIN and stromal nuclei and elevated Tgfb1 mRNA levels (Supplemental Figure 2 and Supplemental Figure 3A ). In both GEMs, p-RB was detected in 76% of Ki67-positive PCCs that coexpressed nuclear p-Smad2 (Supplemental Figure  3 , B-D), whereas in KRC pancreata, which also overexpress TGF-β1 (18), p-Smad2 was detected in stromal cells and all Ki67-positive PanIN and mPDAC cells (Supplemental Figure 4A ). Thus, inactivation of RB removes negative growth restraints, including those mediated by p21 Waf1 , thereby enhancing proliferation in PCCs with active TGF-β signaling.
RB loss impairs TGF-β growth inhibition but not Smad-dependent signaling. KRAS mutations are very frequent (95%) in hPDAC (24) and are the initiating event in KC, KPC, KIC, and KRC GEMs (14, (16) (17) (18) . To investigate the effects of loss of RB function on TGF-β signaling in the context of oncogenic Kras, we used three RB-deficient murine PCCs established from KRC tumors (KRC1017, KRC1022-4, and KRC1022-5), two of which (KRC1022-4 and KRC1022-5) were of clonal origin. We found that TGF-β1 failed to inhibit proliferation in KRC1017 and KRC1022-5 cells and enhanced proliferation in KRC1022-4 cells by approximately 32% (Figure 2A ). TGF-β1 also failed to induce cell cycle arrest and caused an average increase of 9% in the S phase in the three cell lines ( Figure 2B Figure 5B ).
We transduced KRC PCCs with a lentiviral construct encoding HA-tagged murine RB (HA-RB), which expressed Rb1 mRNA at the same level as that observed in KC PCCs (Supplemental Figure  5C ) and partially restored TGF-β1-mediated growth inhibition ( Figure 2 , D and E). By contrast, sham-transduced KRC cells were either refractory to TGF-β1 (KRC1017) or were growth stimulated (KRC1022-4) (Supplemental Figure 4B ). Moreover, we found that transfection with a construct encoding RB in which all potential phosphorylated sites were mutated to glutamate (25) did not restore TGF-β1-mediated growth inhibition ( Figure 2F ). Thus, functional RB is necessary for the cytostatic functions of TGF-β1 in KRC cells, consistent with previous findings in fibroblasts (26) . Yet, in serumstarved KRC cells, we found that TGF-β1 induced Smad2 phosphorylation ( Figure 3A ), enhanced Smad2/3/4 nuclear translocation ( Figure 3B ), and increased Smad transcriptional activity, as demonstrated using two Smad-dependent luciferase reporter constructs, SBE4-Luc and p3TP-Lux (Supplemental Figure 4C ). Moreover, in KRC mPDAC and PanIN, we detected phosphorylated Smad3 (p-Smad3) (Supplemental Figure 4D ) in the nuclei, indicating that RB loss did not abrogate canonical TGF-β signaling in vivo.
RB loss combined with oncogenic Kras leads to aberrant cell cycle regulation by TGF-β1. TGF-β exerts its antimitogenic functions by inhibiting cyclin-dependent kinases (CDKs) primarily through CDK inhibitor (CKI) upregulation (21) , but also through cyclin D1 downregulation (27) . These events occur upstream of RB, leading to its activation through dephosphorylation, repressing E2F, and inducing cell cycle arrest. Therefore, we next evaluated the effects of TGF-β1 on cyclin D1, CKI, and CDK expression in KRC cells. We found that cyclin D1 was downregulated by TGF-β1 in KRC cells ( Figure 3C ), whereas p21 Waf1 induction was minimal ( Figure  3D ). Although TGF-β1 did not induce p27 Kip1 , p15 Ink4b , CDK2, CDK4, or CDK6 in KC or KRC cells ( Figure 3 , D and E), basal CDK2 levels were increased in KRC cells compared with KC cells ( Figure 3E ). Moreover, nuclear CDK2 immunoreactivity was present in KRC PanIN and mPDAC, whereas CDK4 and CDK6 exhibited weak immunoreactivity (Supplemental Figure 4E ). Thus, in spite of functional pathways that downregulate cyclin D1, RB loss is associated with increased CDK2 expression and impaired TGF-β1-mediated upregulation of p21 Waf1 .
TGF-β1 promotes the proliferation of KRC cells in 3D culture. To determine whether TGF-β exerts direct mitogenic effects on KRC cells, we examined TGF-β1 actions on colony formation and growth in 3D culture (28) . We found that both KRC1017 and KRC1022-4 cells formed sphere-like colonies that grew between days 7 and 14 ( Figure 4A ). TGF-β1 colony size was markedly increased within 7 days, with each colony displaying a disorganized morphology associated with bud-like, invasive projections ( Figure 4A ). Compared with controls, TGF-β1-treated colonies were 76% larger by day 14 ( Figure 4B ), and nuclei in the control and TGF-β1-treated colonies frequently coexpressed p-Smad2 and Ki67 ( Figure 4C ). We observed that TGF-β1 also increased proliferating cell nuclear antigen (PCNA) levels in KRC cells grown in 3D culture ( Figure 4D ), confirming that TGF-β1 enhances PCC proliferation. By contrast, TGF-β1 failed to enhance the growth of RB-restored KRC cells ( Figure 4E ). SB505124, a TGF-β type I receptor inhibitor (TβRI) (29) , decreased the number and size of control KRC colonies, markedly attenuated TGF-β1-induced colony growth ( Figure 5, A and B) , and prevented TGF-β1-mediated Smad2 phosphorylation ( Figure 5C ). TGF-β1 also enhanced AKT (S473), p70 S6 kinase (T421/S424 and T389), Src (Y419) ( Figure 5D ), and ERK1/2 (Supplemental Figure 6A ) phosphorylation in KRC cells, indicating that TGF-β1 also activated non- canonical signaling. Moreover, PI3K (LY294002) and Src (dasatinib) inhibition reduced basal and TGF-β1-enhanced growth by 50% and 60%, respectively ( Figure 5E ), indicating that PI3K and Src activation contributes, in part, to the mitogenic effects of TGF-β1. Although the MEK1/2 inhibitor U0126, which inhibits ERK1/2, and the SAPK inhibitors SB203580 and SP600124, which inhibit p38/SAPK and JNK/SAPK, respectively, failed to block TGF-β1-enhanced cell growth ( Figure 6E ), the combination of U0126 with PI3K or Src inhibitors suppressed TGF-β1-induced proliferation (Supplemental Figure 6B) .
TGF-β1 enhances KRC growth, in part, through Wnt7b. TGF-β pathways crosstalk with Wnt pathways (30) , and aberrant Wnt pathway activation is important in PDAC pathobiology (8, 9, 31, 32) . Moreover, KRC cells express all three TGF-βs, including high TGF-β2 levels (18) . We therefore performed gene set enrichment analysis (GSEA) of array data, which revealed that compared with KC cells, genes upregulated in KRC cells correlated strongly with activated TGF-β and TGF-β/Wnt signaling ( Figure 6 , A and B). Wnt pathway activation was evidenced by elevated expression of Wnt7b and Wnt receptors Fzd2, 3, 6, and 9 compared with their expression in KC cells (Supplemental Figure 7) . Importantly, KRC cells expressed active β-catenin that was devoid of phosphates at GSK3β-targeted residues and of inactive (phosphorylated) GSK3β (p-GSK3β), and the levels of p-GSK3β were increased by TGF-β1 ( Figure 6C ). TGF-β1 also increased TOPFlash reporter activity ( Figure 6D ), indicating that TGF-β1 enhances canonical Wnt signaling in KRC cells. Moreover, we observed that IWP-2, a Wnt secretion inhib- itor (33) , and secreted Frizzled-related protein 1 (sFRP1), a Wnt antagonist (34) , markedly attenuated TGF-β1-stimulated growth of KRC1022-4 cells in 3D culture ( Figure 6E ).
Given the above, we next focused on Wnt7b, a mitogen (35, 36) whose expression is increased in human PCC lines (36) (37) (38) . We confirmed by quantitative PCR (qPCR) that KRC cells expressed high Wnt7b mRNA levels as compared with KC cells ( Figure 7A ). Moreover, Wnt7b mRNA and protein levels were further increased by TGF-β1 ( Figure 7 , B and C). Conversely, inhibition of TβRI signaling with SB505124 or incubation with an anti-TGF-β2 neutralizing antibody suppressed basal Wnt7b mRNA levels (Figure 7 , D and E). In silico analysis revealed that the murine Wnt7b promoter harbored two Smad binding elements (SBEs) at -903 bp (SBE1) and -771 (SBE2). Moreover, in murine PCCs derived from tumors in a Kras-driven GEM that lacks Smad4 (15) , we found that basal Wnt7b mRNA levels were low and not inducible by TGF-β1 (Figure 7 , A and F), suggesting that PCC-derived TGF-βs may enhance Wnt7b expression through Smad4-dependent pathways. In support of this conclusion, TGF-β1 increased the activity of a wild-type, but not a mutant, Wnt7b promoter-luciferase construct in KRC cells and failed to increase luciferase activity in KSC cells ( Figure 7G ). Moreover, in ChIP assays, Smad2/3/4 complexes were associated with the Wnt7b promoter in TGF-β1-stimulated KRC cells ( Figure 7H ). Given that Smad4 is mutated in 55% of PDACs (3), we evaluated PDAC tissues for Wnt7b and Smad4 coexpression. Wnt7b exhibited moderate-to-strong immunoreactivity in PCCs in 28 of 58 PDACs, and only these samples exhibited nuclear Smad4 immunoreactivity ( Figure 7I ). By contrast, when Smad4 was undetectable, Wnt7b immunoreactivity was negative to weak ( Figure 7I ).
We next assessed the role of Wnt7b in TGF-β1-stimulated mitogenesis by silencing Wnt7b in clonal KRC1022-4 cells. siRNA targeting of murine Wnt7b reduced Wnt7b mRNA levels (62%) and abrogated TGF-β1-induced TOPFlash activity ( Figure 8, A and B) . Moreover, Wnt7b silencing partially restored the growth inhibitory effects of TGF-β1 in KRC cells grown on plastic ( Figure 8C ) and markedly attenuated TGF-β1-enhanced growth in 3D culture (Figure 8, D and E) , indicating that the mitogenic effects of TGF-β1 are mediated in part by Wnt7b. spindly morphology, and disruption of tightly packed epitheliallike arrangements ( Figure 9A ). Although TGF-β1 did not markedly decrease E-cadherin expression ( Figure 9B ), we found that it caused its redistribution to the cytoplasm with predominant TGF-β1 induces epithelial-to-mesenchymal transition and invasion in KRC cells. We next sought to determine whether TGF-β1 induces epithelial-to-mesenchymal transition (EMT) and invasion in KRC cells. Within 48 hours, TGF-β1 promoted cell elongation, a not induce RB dysfunction, and that in addition to exerting paracrine effects on the tumor microenvironment, TGF-βs may exert autocrine effects that activate cell-autonomous pathways in PCCs.
There are multiple mechanisms by which RB can be inactivated or suppressed in PDAC. First, based on loss of the CDKN2A gene, the RB/p16 pathway was reported to be inactive in 98% of PDAC cases (42) . Second, the presence of oncogenic KRAS in 95% of PDACs (24) , occurring in conjunction with the overexpression of mitogenic tyrosine kinase receptors and their ligands (6) , could combine to induce RB phosphorylation and inactivation. Third, 50% of PDAC cases overexpress Smad7, which suppresses TGF-β1-mediated growth inhibition by maintaining RB in a hyperphosphorylated state (23) . Fourth, microRNA-132 (miRNA-132) and miRNA-212 are upregulated in PDAC and act to suppress RB expression in PCCs (43) . Fifth, PDACs occasionally harbor RB1 mutations (20) . In the present study, we confirm our previous finding that RB activation is crucial for TGF-β-mediated growth inhibition (23) . Thus, cells devoid of RB (KRC cells) were no longer growth inhibited by TGF-β, and growth inhibition was restored when RB was reexpressed to levels similar to those present in KC cells. Moreover, using a mutant RB construct, we demonstrated that RB genetic ablation is equivalent to phosphorylation-mediated inhibition. Collectively, these findings indicate that in addition to interfering with negative growth constraints, RB loss converted TGF-β to a PCC mitogen.
Previous studies have shown that TGF-β1 stimulates the proliferation of human prostate epithelial cells that harbor mutated HRAS (44) , that tyrosine phosphorylation on type II TGF-β receptor (TβRII) leads to the recruitment of GRB2, which allows TGF-β to stimulate proliferation in breast cancer cells (45) , and that high levels of the type III TGF-β receptor (TβRIII) enable TGF-β and BMP-2 to enhance proliferation and suppress their ability to upregulate p21 and p27 (46) . By contrast, several lines of evidence in the present study demonstrate that in the absence of functional RB, TGF-β1 enhances mitogenesis by activating both noncanonical and canonical TGF-β signaling. First, the mitogenic effect of TGF-β was blocked by TGF-β receptor kinase inhibition with SB505124, indicating that it required TβRI activation. Second, we observed that TGF-β activated noncanonical pathways (41) that have crucial roles in mitogenesis (MEK/ERK), cell survival (PI3K/p-AKT), and invasion/metastases (p-Src[Y419]). Third, we found that TGF-β-induced mitogenesis was partially blocked by targeting either PI3K or Src, MEK and PI3K, or MEK and Src, confirming that these pathways are important mediators of TGF-β-induced mitogenesis. Fourth, TGF-β1-induced proliferation was markedly attenuated by IWP-2-mediated inhibition of Wnt processing and secretion and by sFRP-1-mediated Wnt ligand sequestration, pointing to a Wnt-mediated mechanism for TGF-β-activated mitogenesis. Fifth, we found that TGF-β1 increased Wnt7b expression, whereas silencing Wnt7b markedly attenuated TGF-β1-induced mitogenesis and TOPFlash activity, confirming the role of Wnt7b in this novel pathway. Mechanistically, TGF-β1 enhanced Wnt7b promoter activity in a Smad4-dependent manner, as we confirmed by using luciferase readout and ChIP assays and by documenting the absence of a response in Smad4-null cells. Thus, loss of RB function converts TGF-β1 from an inhibitor of PCC proliferation that promotes tumor growth through paracrine actions, to a mitogen that also acts directly to stimulate PCC proliferation by activating canonical and noncanonical TGF-β signaling cascades ( Figure 10 ). perinuclear localization ( Figure 9A ). TGF-β1 also upregulated N-cadherin in KRC1017 and KRC1022-5 and the EMT-inducing transcription factors ZEB1 and SNAIL in all three cell lines ( Figure 9B ). In parallel, we found that KRC cell invasion was enhanced by an average of 758% ( Figure 9C ). Given the role of Wnts in EMT, invasion, and metastasis (39), we next assessed the role of Wnt7b in TGF-β1-enhanced invasion of KRC cells. In KRC1022-4 cells transfected with nontargeting control siRNA, TGF-β1 enhanced invasion by 768%, and this effect was blocked by siRNA targeting of Wnt7b (Figure 9C) . These results indicate that TGF-β1 promotes EMT and enhances invasion in KRC cells in a Wnt7b-dependent manner.
TβRI inhibition attenuates tumor growth in vivo. We next evaluated the impact of TGF-β signaling blockade on tumor growth and metastasis in the context of an intact immune system using KRC1017 and KRC1022-4 cells in a syngeneic orthotopic model. Treatments began on day 10 after intrapancreatic PCC injection, when the mean volumes of KRC1017 and KRC1022-4 tumors were 57 mm 3 and 55 mm 3 , respectively (Supplemental Figure 8A) . By day 17, tumors in vehicle-treated mice had grown by 810% and caused abundant ascites, whereas in SB505124-treated mice, tumors had grown by 195% and were devoid of ascites ( Figure  9 , D and E). Overall, 100% of vehicle-treated mice succumbed to disease by day 26 ( Figure 9F ) and frequently (12 of 14) displayed abundant peritoneal seeding (Supplemental Figure 8B) . Moreover, some mice (4 of 14) displayed grossly evident liver metastases, and three of these mice harbored multiple pulmonary micro-metastases (Supplemental Figure 8C) . By contrast, SB505124-treated mice survived as long as 50 days ( Figure 9F ) and never exhibited ascites ( Figure 9D ), peritoneal seeding (Supplemental Figure 8B) , or distant metastases. These tumors exhibited decreased PCC proliferation ( Figure 9G and Supplemental Figure 9A ), stroma formation (Supplemental Figure 8 , D and E), and N-cadherin and ZEB1 immunoreactivity (Supplemental Figure 9B ). We found WNT7b immunoreactivity to be heterogeneous, with foci of mild, moderate, and strong intensity. Compared with PCCs in vehicle-treated tumors, we observed that Wnt7b immunoreactivity was markedly reduced in the SB505124-treated group (Supplemental Figure 9 , C and D), indicating that SB505124 suppressed Wnt7b expression in vivo. Thus, disruption of TGF-β signaling in a syngeneic model with an intact immune system induces multiple beneficial actions.
Discussion
One of the hallmarks of cancer is an insensitivity to growth inhibitory pathways (40) . In the case of TGF-βs, loss of growth inhibition has been associated with an enhanced tumor progression attributed to its paracrine effects on the tumor microenvironment (41) . Here, we determined that both Smad2 and RB were frequently phosphorylated in proliferating cancer cells and stromal cells in hPDAC. Proliferating cancer cells and PanIN cells in mPDAC in Kras G12D -driven models that lack either p16 Ink4a (KIC) or p53 (KPC) also exhibited p-Smad2 and p-RB, and p-Smad2 was also abundant in the stromal cells. Moreover, PanIN, stroma, and PCCs in KRC mPDAC (devoid of RB) were highly proliferative (18) and exhibited many p-Smad2-and p-Smad3-positive nuclei. By contrast, PanIN in a murine model driven by Kras G12D alone were not highly proliferative and exhibited abundant p-Smad2 phosphorylation and low levels of p-RB. Taken together, these observations indicate that RB dysfunction is common in hPDAC and in biologically aggressive GEMs of PDAC (16, 17) , that Kras G12D alone does tions in hPDAC that lead to increased Wnt/β-catenin activity in certain cancers (49, 50) , the relevance of the current observations to hPDAC is underscored by the presence of moderate-to-strong Wnt7b immunoreactivity in the cancer cells in 45% of hPDAC tissues, which correlated with the presence of nuclear Smad4. Moreover, hPDACs exhibit aberrant Wnt/β-catenin activation (31, 51) , and some cultured human PCCs have high β-catenin activity (36) and express elevated levels of Wnt7b (36) (37) (38) . Taken together, these data indicate that TGF-βs can act on PCCs in an autocrine manner to enhance Wnt7b expression and to crosstalk with Wnt signaling cascades.
PCCs often exhibit mesenchymal cell features, especially following EMT induction by TGF-β1, leading to enhanced invasion and expression of markers associated with tumor-initiating cells (52) . We found that in KRC cells, in addition to enhancing proliferation, TGF-β1 readily induced EMT, evidenced morphologically and by decreased E-cadherin expression and its redistribution to the cytoplasm, as well as by increased N-cadherin, ZEB1, and SNAIL expression. Moreover, in vivo, the administration of SB505124 ten days after PCC injection into the pancreas greatly attenuated PCC proliferation, tumor growth, metastasis, and expression of the mesenchymal markers N-cadherin and ZEB1. We found that SB505124 also markedly decreased Wnt7b expression and suppressed stroma formation in the orthotopic tumors, and targeting the stroma in PDAC may facilitate drug delivery to the cancer cells within the tumor mass (53) . Therefore, our findings indicate that targeting TGF-β signaling exerts multiple beneficial effects that prolong survival, disrupt crosstalk between TGF-β and Wnt, inhibit the metastatic process, and may also allow for improved delivery of chemotherapeutic agents.
TGF-β and Wnt ligands have been implicated in maintaining a pool of tumor-initiating cells that exhibit enhanced metastatic potential (39) , and it may take 20 years of tumor progression for PDAC to acquire the capacity to form distant metastases (54) . Therefore, our findings suggest that combinatorial targeting of TGF-β and Wnt ligands, such as Wnt7b, may be a useful approach for overcoming RB dysfunction, suppressing metastasis formation, and enhancing the efficacy of other therapeutic strategies in PDAC. Given the advanced stage of PDAC at clinical presentation, our findings also indicate that targeting TGF-β is unlikely to interfere with its tumor suppressor functions, since these functions are lost, and TGF-βs are acting as mitogenic tumor promoters in advanced stages of PDAC.
Methods
Mice. KRC mice, originally described as Rb/K mice, were generated as described (18) . Conditional Ink4a/Arf LoxP/LoxP and Smad4 LoxP/LoxP mice were provided by N. Bardeesy (Harvard Medical School, Boston, Massachusetts, USA), and Trp53 LoxP/LoxP mice were from the NCI Mouse Repository (strain Active RB represses the transcription of E2F-regulated genes during the G1 phase of the cell cycle (47) , whereas p21 Waf1 inactivates cyclin/CDK complexes during G1, S, and G2 phases, inhibits PCNA-dependent DNA synthesis, and inactivates E2F (48) . Consequently, under nonpathological conditions, RB and p21 Waf1 induce cell cycle arrest. However, p53 and Smad4 are frequently mutated in hPDAC (3), and p53 and TGF-β are major inducers of p21 Waf1 . Indeed, we found that p21 Waf1 expression was attenuated in many hPDAC cases and in KPC, KIC, and KRC mPDACs. Moreover, RB reexpression failed to restore TGF-β1-mediated induction of p21 Waf1 (not shown), indicating that RB-independent mechanisms contribute to its attenuated expression. By contrast, p21 Waf1 was abundant in KC mPDAC. These observations suggest that attenuated p21 Waf1 expression is common in hPDAC and mPDAC whenever oncogenic KRAS is combined with tumor suppressor gene loss. Given that p21 Waf1 preferentially inactivates CDK2 (48) , that KRC cells had elevated CDK2 levels, and that KRC PanIN and mPDAC exhibited nuclear CDK2 immunoreactivity, our observations also suggest that p21 Waf1 dysregulation, combined with increased CDK2 expression, may further enhance PCC proliferation in KRC mPDAC.
KRC cells express high levels of TGF-β2, Wnt7b, and total β-catenin and exhibit strong nuclear p-Smad2 immunoreactivity, raising the possibility that TGF-βs act in an autocrine manner to upregulate deleterious TGF-β and Wnt signaling. In agreement with this conclusion, we found that Wnt7b expression in KRC cells was suppressed by SB505124 and by a TGF-β2-neutralizing antibody. TGF-β1 also increased Wnt reporter activity, consistent with activation of canonical Wnt/β-catenin pathways, and this effect was abrogated by Wnt7b silencing. Similarly, we observed that TGF-β1 enhanced invasion in KRC cells, and this effect was also blocked by Wnt7b silencing. Moreover, our GSEA analysis indicated that the gene expression profile of KRC cells exhibited statistically significant concordance with genes upregulated by TGF-β and Wnt pathway activation ( Figure 6,  A and B) . Although there are no reports of the APC or axin muta-
Figure 10
TGF-β1 enhances PCC proliferation, invasion, and EMT when RB is inactive. Phosphorylation of RB, Smad7 overexpression, suppression of RB by miRNA-132 and miRNA-212, and mutations in the RB1 gene (rare) are mechanisms by which RB can be inactivated in PCCs, leading to loss of TGF-β growth inhibition. Inactive RB, combined with TGF-β, increases Wnt7b expression through canonical (Smad4-dependent) TGF-β signaling pathways, which increases PCC proliferation EMT and invasion. TGF-β also enhances PCC proliferation through the activation of noncanonical signaling pathways, including ERK, Src, and PI3K.
3D culture. KRC cells were grown in 3D culture (28) . Four days after plating and every three days thereafter, cells were treated with control media or media with TGF-β1, with or without inhibitors. The final concentration of DMSO in all experiments was 0.05%. For Wnt7b silencing, KRC cells were plated, transfected with control siRNA or Wnt7b-targeting siRNA for 24 hours, then grown in 3D culture. Colony growth was quantified on day 14 using the MTT growth assay (28) , and the colony area was determined using ImageProPlus, version 7.0. The area of control-treated colonies was normalized to 100%, and changes in growth were calculated as a percentage of control.
For immunofluorescence, colonies were fixed in 10% formalin, embedded, and frozen (Tissue-Tek O.C.T. Compound). Ten-micrometer sections were prepared using a Leica CM1900 cryostat and stained for phospho-Smad2 and Ki67.
ChIP assays. KRC cells were plated in 15-cm dishes, serum starved, then treated with TGF-β1 (0.5 nM, 24 hours). ChIP assays were performed with control IgG (Santa Cruz Biotechnology Inc.) or Smad2/3 and 4 antibodies using a Simple ChIP Enzymatic Chromatin IP kit (Cell Signaling Technology) according the manufacturer's recommendations. The Wnt7b promoter was PCR amplified (Supplemental Table 1 ). PCR products were run on an agarose gel, bands were quantified with ImageJ software (NIH), and data were normalized to input.
Microarray and GSEA analysis. Three Agilent whole-mouse genome microarrays with total RNA from three different RNA isolations from KC (Cy3-labeled) and KRC (Cy5-labeled) cells were performed by Miltenyi Biotec. All bioinformatic and statistical analyses were performed by Miltenyi Biotec. Briefly, intensity values were extracted, converted to log2 scale, and locally weighted regression (LOESS) normalization was performed. Heatmaps of each microarray were generated, reflecting normalized intensity values. Unpaired Student's t tests with equal variance were used to test log2-normalized data for significant differences. P values were subjected to multiple testing (Benjamini-Hochberg) correction to reduce the false discovery rate (FDR). P < 0.001 was considered statistically significant. Microarray data are available at the European Bioinformatics Institute (accession number E-MEXP-3988).
For GSEA, normalized, log2-transformed data were prepared in GSEA format (57) . A custom chip file that mapped probesets from this array to HUGO gene symbols was generated. GSEA was run and compared with gene sets upregulated by TGF-β1 (58) or TGF-β1 and Wnt3a (59) using version 2.0.13 of the command line jar application on collections from the Molecular Signatures Database, version 4.0 (57, 60) . Significant gene sets with a family-wise error (FWER) less than 0.05 were then identified.
Invasion assays. Invasion assays were performed as described (55) . Orthotopic model. KRC cells (200,000 cells) were injected into the pancreas of 28 (20 males, 8 females) 10-week-old syngeneic mice using KRC1017 and KRC1022-4 cells (10 males, 4 females per cell line). On day 10, mice were randomized to vehicle and SB505124 treatment groups (7 mice per group; 5 males and 2 females in each). Before treatment began, tumors were imaged using Vevo2100 high-resolution ultrasound (VisualSonics). Mice were injected i.p. daily with vehicle (75% DMSO, 25% saline) or 10 mg/kg SB505124, and 7 days later tumors were imaged. 3D abdominal scans were acquired on days 10 (pretreatment) and 17 (1 week after treatment), and tumor volumes were calculated using Vevo2100 System software. Daily injections continued up to day 50, and mice were sacrificed as they became moribund. For immunofluorescence, 5 of 7 tumors per group were stained as described above. Masson's trichrome staining was performed using a Chromaview kit (Richard-Allan Scientific). Images from four different fields of each tumor were acquired at ×20 magnification.
Statistics. One-way ANOVA with Tukey's post-hoc test and 1-tailed Student's t tests were used to test for significant differences using Sigma Plot version 11.0 software (Systat Software). All statistics were calculated on
